Kandur, YaşarAlpcan, AyşegülYozgat, MehmetTursun, Serkan2025-01-212025-01-2120211307-44902148-3566https://doi.org/10.12956/tchd.833625https://search.trdizin.gov.tr/tr/yayin/detay/1194460https://hdl.handle.net/20.500.12587/21983We describe a case of a patient with Chronic Kidney Disease who developed polycythemia due to Erythropoiesis Stimulating Agents overuse during COVID-19 isolation. A 12-year-old male had not been able to attend routine controls since had been in isolation for 4 months after the COVID-19 outbreak. He had continued to take Erythropoiesis- Stimulating Agents during that period at the starting dose of 150 U/kg/week. He had been on peritoneal dialysis in the last year because of end-stage renal failure. Laboratory investigation revealed a hemoglobin (Hb) level of 20.8 g/dl, hematocrit level of 66%, creatinine level of 6.5 mgr/dl. He underwent daily phlebotomy sessions (10cc/kg/session). During this period aspirin was also started (5mg/kg). After 5 sessions his Hb level decreased to 14 gr/dl and hematocrit to 40%. Pediatric nephrologist should be aware that there is a potential risk of polycythemia with Erythropoiesis Stimulating Agents when Hb level is not appropriately followed on a routine basis.eninfo:eu-repo/semantics/openAccessKadın Hastalıkları ve DoğumÜroloji ve NefrolojiHematolojiSağlık Bilimleri ve HizmetleriPediatriArticle15543443610.12956/tchd.8336251194460